Fulltext

An evaluation of dose equivalence between synchrotron microbeam radiation therapy and conventional broad beam radiation using clonogenic and cell impedance assays

Ibahim MJ 1 , Crosbie JC 2 , Yang Y 3 , Zaitseva M 3 , Stevenson AW 4 , Rogers PA 3 Show all authors , Paiva P 3

Affiliations 

  • 1 Department of Obstetrics and Gynaecology, Royal Women's Hospital, University of Melbourne, Parkville, Victoria, Australia; Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Sungai Buloh, Selangor, Malaysia
  • 2 Department of Obstetrics and Gynaecology, Royal Women's Hospital, University of Melbourne, Parkville, Victoria, Australia; William Buckland Radiotherapy Centre, Alfred Hospital, Melbourne, Australia
  • 3 Department of Obstetrics and Gynaecology, Royal Women's Hospital, University of Melbourne, Parkville, Victoria, Australia
  • 4 Australian Synchrotron Imaging and Medical Beamline, Clayton, Australia; CSIRO Materials Science & Engineering, Clayton, Australia
PLoS One, 2014;9(6):e100547.
PMID: 24945301 DOI: 10.1371/journal.pone.0100547

Abstract

High-dose synchrotron microbeam radiation therapy (MRT) has shown the potential to deliver improved outcomes over conventional broadbeam (BB) radiation therapy. To implement synchrotron MRT clinically for cancer treatment, it is necessary to undertake dose equivalence studies to identify MRT doses that give similar outcomes to BB treatments.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications